<div class="qMYqUG_convSearchResultHighlightRoot">
<div class="" data-turn-id-container="request-WEB:74b3982d-636b-41f8-a7f7-75919c1a6292-7" data-is-intersecting="true">
<section class="text-token-text-primary w-full focus:outline-none has-data-writing-block:pointer-events-none [&amp;:has([data-writing-block])&gt;*]:pointer-events-auto R6Vx5W_threadScrollVars scroll-mb-[calc(var(--scroll-root-safe-area-inset-bottom,0px)+var(--thread-response-height))] scroll-mt-[calc(var(--header-height)+min(200px,max(70px,20svh)))]" dir="auto" data-turn-id="request-WEB:74b3982d-636b-41f8-a7f7-75919c1a6292-7" data-turn-id-container="request-WEB:74b3982d-636b-41f8-a7f7-75919c1a6292-7" data-testid="conversation-turn-12" data-scroll-anchor="false" data-turn="assistant">
<div class="text-base my-auto mx-auto pb-10 [--thread-content-margin:var(--thread-content-margin-xs,calc(var(--spacing)*4))] @w-sm/main:[--thread-content-margin:var(--thread-content-margin-sm,calc(var(--spacing)*6))] @w-lg/main:[--thread-content-margin:var(--thread-content-margin-lg,calc(var(--spacing)*16))] px-(--thread-content-margin)">
<div class="[--thread-content-max-width:40rem] @w-lg/main:[--thread-content-max-width:48rem] mx-auto max-w-(--thread-content-max-width) flex-1 group/turn-messages focus-visible:outline-hidden relative flex w-full min-w-0 flex-col agent-turn">
<div class="flex max-w-full flex-col gap-4 grow">
<div class="min-h-8 text-message relative flex w-full flex-col items-end gap-2 text-start break-words whitespace-normal outline-none keyboard-focused:focus-ring [.text-message+&amp;]:mt-1" dir="auto" tabindex="0" data-message-author-role="assistant" data-message-id="7d2d2ce8-9d23-4827-b206-1c56f1847bc4" data-message-model-slug="gpt-5-5" data-turn-start-message="true">
<div class="flex w-full flex-col gap-1 empty:hidden">
<div class="markdown prose dark:prose-invert wrap-break-word w-full light markdown-new-styling">
<h2 data-section-id="1ilo70w" data-start="0" data-end="33"><strong>Presbyopia Market Insights</strong></h2>
<p data-start="35" data-end="691">The <a href="https://www.delveinsight.com/report-store/presbyopia-market-insight"><strong>Presbyopia market</strong></a> is witnessing significant transformation with the emergence of pharmacological therapies that offer alternatives to traditional corrective devices such as reading glasses and <a href="https://www.delveinsight.com/report-store/contact-lenses-market"><strong>contact lenses</strong></a>. The market across the 7MM was valued at nearly USD 11 billion in 2025 and is projected to grow at a CAGR of 4.9% during 2026&ndash;2036. Growth is primarily driven by the rising aging population, increasing digital device usage, and expanding adoption of minimally invasive treatment options. Eye drop therapies have emerged as a major market segment, accounting for nearly USD 3 billion in revenue in 2025, led by pioneering products such as VUITY.</p>
<h3 data-start="693" data-end="718"><strong data-start="693" data-end="718">Key Market Highlights</strong></h3>
<ul data-start="719" data-end="998">
<li data-section-id="1mkq2lx" data-start="719" data-end="762">CAGR of 4.9% projected during 2026&ndash;2036</li>
<li data-section-id="1ug2b35" data-start="763" data-end="813">7MM market size reached USD 11 billion in 2025</li>
<li data-section-id="1fbjuc0" data-start="814" data-end="878">Eye drop therapies generated nearly USD 3 billion in revenue</li>
<li data-section-id="vmsg4r" data-start="879" data-end="941">Rising adoption of non-invasive pharmacological treatments</li>
<li data-section-id="1lfq6v1" data-start="942" data-end="998">Increasing product launches driving market expansion</li>
</ul>
<h2 data-section-id="1uke4po" data-start="1005" data-end="1044"><strong>Presbyopia Epidemiology Insights</strong></h2>
<p data-start="1046" data-end="1685">Presbyopia is one of the most common age-related vision disorders, predominantly affecting individuals above 40 years of age. In 2025, total diagnosed prevalent cases across the 7MM were estimated at approximately 280,000. EU4 and the UK accounted for the highest share at 47%, followed by the United States at 42% and Japan at 11%. The disease burden is expected to increase steadily during the forecast period due to population aging, lifestyle changes, and greater awareness regarding eye health. Epidemiological trends also indicate a slight female predominance, with the highest prevalence observed among individuals aged 60&ndash;69 years.</p>
<h3 data-start="1687" data-end="1718"><strong data-start="1687" data-end="1718">Key Epidemiology Highlights</strong></h3>
<ul data-start="1719" data-end="2008">
<li data-section-id="14n09ao" data-start="1719" data-end="1786">Total diagnosed prevalent cases in the 7MM reached 280K in 2025</li>
<li data-section-id="e1nldq" data-start="1787" data-end="1839">EU4 and the UK accounted for nearly 47% of cases</li>
<li data-section-id="mqfjkb" data-start="1840" data-end="1891">US contributed approximately 42% of total cases</li>
<li data-section-id="1yc2s13" data-start="1892" data-end="1948">Japan represented around 11% of diagnosed prevalence</li>
<li data-section-id="o6vqy9" data-start="1949" data-end="2008">Highest prevalence observed in the 60&ndash;69-year age group</li>
</ul>
<h2 data-section-id="11wue5z" data-start="2015" data-end="2064"><strong>Presbyopia Pipeline and Emerging Therapies</strong></h2>
<p data-start="2066" data-end="2706">The <a href="https://www.delveinsight.com/report-store/presbyopia-pipeline-insight"><strong>Presbyopia pipeline</strong></a> is expanding rapidly with the development of novel topical therapies aimed at improving near vision through pharmacological modulation of pupil dynamics and accommodation. Following the success of <a href="https://www.delveinsight.com/report-store/vuity-drug-insight-and-market-forecast"><strong>VUITY</strong></a>, multiple companies are advancing next-generation eye drops with improved efficacy, duration, and tolerability profiles. Emerging therapies are focused on enhancing patient convenience while reducing dependence on corrective eyewear. The growing clinical validation of pharmacologic treatments is expected to strengthen physician and patient confidence in non-invasive management approaches over the coming years.</p>
<h3 data-start="2708" data-end="2730"><strong data-start="2708" data-end="2730">Key Pipeline Drugs</strong></h3>
<ul data-start="2731" data-end="3024">
<li data-section-id="yls1b7" data-start="2731" data-end="2840"><strong data-start="2733" data-end="2771">MicroLine (Pilocarpine Ophthalmic)</strong> &mdash; Eyenovia
<ul data-start="2787" data-end="2840">
<li data-section-id="ku4cfu" data-start="2787" data-end="2840">Cholinergic muscarinic receptor agonist | Topical</li>
</ul>
</li>
<li data-section-id="1upnzlf" data-start="2842" data-end="2935"><strong data-start="2844" data-end="2855">GLK-302</strong> &mdash; Glaukos Corporation
<ul data-start="2882" data-end="2935">
<li data-section-id="ku4cfu" data-start="2882" data-end="2935">Cholinergic muscarinic receptor agonist | Topical</li>
</ul>
</li>
<li data-section-id="yatld6" data-start="2937" data-end="3024"><strong data-start="2939" data-end="2955">Phentolamine</strong> &mdash; Opus Genetics
<ul data-start="2976" data-end="3024">
<li data-section-id="23dwr2" data-start="2976" data-end="3024">Investigational presbyopia therapy | Topical</li>
</ul>
</li>
</ul>
<h3 data-start="3026" data-end="3049"><strong data-start="3026" data-end="3049">Pipeline Highlights</strong></h3>
<ul data-start="3050" data-end="3368" data-is-last-node="" data-is-only-node="">
<li data-section-id="bj2oh7" data-start="3050" data-end="3114">Increasing focus on pharmacological correction of presbyopia</li>
<li data-section-id="15io2ha" data-start="3115" data-end="3177">Topical eye drops emerging as major treatment alternatives</li>
<li data-section-id="eahv2c" data-start="3178" data-end="3237">Growing demand for minimally invasive vision correction</li>
<li data-section-id="1e1dl91" data-start="3238" data-end="3301">MicroLine expected to strengthen future treatment landscape</li>
<li data-section-id="6h1z9a" data-start="3302" data-end="3368" data-is-last-node="">Expanding clinical research supporting next-generation therapies</li>
</ul>
</div>
</div>
</div>
</div>
<div class="mt-3 w-full empty:hidden">&nbsp;</div>
</div>
</div>
</section>
</div>
</div>

Presbyopia Market

Presbyopia symptoms, treatment, epidemiology, companies, drugs, infographic is a short guide to understand the problem and market landscape